NCT00245050: Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer |
|
|
| Completed | 3 | 34 | US | pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 04/08 | 09/11 | | |
